Modern insights into ophthalmic manifestations of rheumatic diseases

Abstract

This literature review is devoted to the analysis of modern insights into ophthalmological manifestations (according to the data of foreign scientific literature in the PubMed system for 2017–2020) of the most common rheumatic diseases (rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, systemic scleroderma, systemic vasculitis), which are characterized by damage to all structures of the eye and its adnexa: eyelids, orbital tissues, eyeball tunics, vessels, optic nerve and vitreous. Ocular lesion may be an onset, one of the diagnostic signs, or a biomarker of underlying medical condition.

Keywords

rheumatic diseases / ophthalmological manifestations / biomarker

References

[1] Pathak S, McDermott MF, Savic S. Autoinflammatory diseases: update on classification diagnosis and management. J Clin Pathol. 2017;70(1):1–8. DOI: 10.1136/jclinpath-2016-203810

[2] Pathak S., McDermott M.F., Savic S. Autoinflammatory diseases: update on classification diagnosis and management // J Clin Pathol. 2017. Vol. 70, No. 1. P. 1–8. DOI: 10.1136/jclinpath-2016-203810

[3] Nayak K, Misra M. A review on recent drug delivery systems for posterior segment of eye. Biomed Pharmacother. 2018;107: 1564–1582. DOI: 10.1016/j.biopha.2018.08.138

[4] Nayak K., Misra M. A review on recent drug delivery systems for posterior segment of eye // Biomed Pharmacother. 2018. Vol. 107. P. 1564–1582. DOI: 10.1016/j.biopha.2018.08.138

[5] Kemeny-Beke A, Szodoray P. Ocular manifestations of rheumatic diseases. Int Ophthalmol. 2020;40(2):503–510. DOI: 10.1007/s10792-019-01183-9

[6] Kemeny-Beke A., Szodoray P. Ocular manifestations of rheumatic diseases // Int Ophthalmol. 2020. Vol. 40, No. 2. P. 503–510. DOI: 10.1007/s10792-019-01183-9

[7] Kötter I., Stübiger N., Deuter C. Ocular involvement in rheumatoid arthritis, connective tissue diseases and vasculitis. Z Rheumatol. 2017;76(8):673–681. DOI: 10.1007/s00393-017-0372-7 (In Ger.)

[8] Kötter I., Stübiger N., Deuter C. Augenbeteiligung bei rheumatoider Arthritis, Kollagenosen und Vaskulitiden // Z Rheumatol. 2017. Vol. 76, No. 8. P. 673–681. DOI: 10.1007/s00393-017-0372-7

[9] Caimmi C, Crowson CS, Smith WM, et al. Clinical Correlates, Outcomes, and Predictors of Inflammatory Ocular Disease Associated with Rheumatoid Arthritis in the Biologic Era. J Rheumatol. 2018;45(5):595–603. DOI: 10.3899/jrheum.170437

[10] Caimmi C., Crowson C.S., Smith W.M., et al. Clinical Correlates, Outcomes, and Predictors of Inflammatory Ocular Disease Associated with Rheumatoid Arthritis in the Biologic Era // J Rheumatol. 2018. Vol. 45, No. 5. P. 595–603. DOI: 10.3899/jrheum.170437

[11] Abd-Allah NM, Hassan AA, Omar G, et al. Dry eye in rheumatoid arthritis: relation to disease activity. Immunol Med. 2020;43(2): 92–97. DOI: 10.1080/25785826.2020.1729597

[12] Abd-Allah N.M., Hassan A.A., Omar G., et al. Dry eye in rheumatoid arthritis: relation to disease activity // Immunol Med. 2020. Vol. 43, No. 2. P. 92–97. DOI: 10.1080/25785826.2020.1729597

[13] Rentka A, Nagy A, Harsfalvi J, et al. Association between objective signs and subjective symptoms of dry eye disease in patients with systemic sclerosis. Rheumatol Int. 2017;37(11):1835–1845. DOI: 10.1007/s00296-017-3794-2

[14] Rentka A., Nagy A., Harsfalvi J., et al. Association between objective signs and subjective symptoms of dry eye disease in patients with systemic sclerosis // Rheumatol Int. 2017. Vol. 37, No. 11. P. 1835–1845. DOI: 10.1007/s00296-017-3794-2

[15] Rassi DM, De Paiva CS, Dias LC, et al. Review: MicroRNAS in ocular surface and dry eye diseases. Ocul Surf. 2017;15(4):660–669. DOI: 10.1016/j.jtos.2017.05.007

[16] Rassi D.M., De Paiva C.S., Dias L.C., et al. Review: MicroRNAS in ocular surface and dry eye diseases // Ocul Surf. 2017. Vol. 15, No. 4. P. 660–669. DOI: 10.1016/j.jtos.2017.05.007

[17] Kuklinski E, Asbell PA. Sjogren’s syndrome from the perspective of ophthalmology. Clin Immunol. 2017;182:55–61. DOI: 10.1016/j.clim.2017.04.017

[18] Kuklinski E., Asbell P.A. Sjogren’s syndrome from the perspective of ophthalmology // Clin Immunol. 2017. Vol. 182. P. 55–61. DOI: 10.1016/j.clim.2017.04.017

[19] Şahin M, Yüksel H, Şahin A, et al. Evaluation of the Anterior Segment Parameters of the Patients with Scleroderma. Ocul Immunol Inflamm. 2017;25(2):233–238. DOI: 10.3109/09273948.2015.1115079

[20] Şahin M., Yüksel H., Şahin A., et al. Evaluation of the Anterior Segment Parameters of the Patients with Scleroderma // Ocul Immunol Inflamm. 2017. Vol. 25, No. 2. P. 233–238. DOI: 10.3109/09273948.2015.1115079

[21] Mayali H, Altinisik M, Sencan S, et al. A multimodal ophthalmic analysis in patients with systemic sclerosis using ocular response analyzer, corneal topography and specular microscopy. Int Ophthalmol. 2020;40(2):287–296. DOI: 10.1007/s10792-019-01173-x

[22] Mayali H., Altinisik M., Sencan S., et al. A multimodal ophthalmic analysis in patients with systemic sclerosis using ocular response analyzer, corneal topography and specular microscopy // Int Ophthalmol. 2020. Vol. 40, No. 2. P. 287–296. DOI: 10.1007/s10792-019-01173-x

[23] Cao Y, Zhang W, Wu J, et al. Peripheral Ulcerative Keratitis Associated with Autoimmune Disease: Pathogenesis and Treatment. J Ophthalmol. 2017;2017:7298026. DOI: 10.1155/2017/7298026

[24] Cao Y., Zhang W., Wu J., et al. Peripheral Ulcerative Keratitis Associated with Autoimmune Disease: Pathogenesis and Treatment // J Ophthalmol. 2017. Vol. 2017. P. 7298026. DOI: 10.1155/2017/7298026

[25] Watanabe R, Ishii T, Yoshida M, et al. Ulcerative keratitis in patients with rheumatoid arthritis in the modern biologic era: a series of eight cases and literature review. Int J Rheum Dis. 2017;20(2):225–230. DOI: 10.1111/1756-185X.12688

[26] Watanabe R., Ishii T., Yoshida M., et al. Ulcerative keratitis in patients with rheumatoid arthritis in the modern biologic era: a series of eight cases and literature review // Int J Rheum Dis. 2017. Vol. 20, No. 2. P. 225–230. DOI: 10.1111/1756-185X.12688

[27] Timlin HM, Hall HN, Foot B, Koay P. Corneal perforation from peripheral ulcerative keratopathy in patients with rheumatoid arthritis: epidemiological findings of the British Ophthalmological Surveillance Unit. Br J Ophthalmol. 2018;102(9):1298–1302. DOI: 10.1136/bjophthalmol-2017-310671

[28] Timlin H.M., Hall H.N., Foot B., Koay P. Corneal perforation from peripheral ulcerative keratopathy in patients with rheumatoid arthritis: epidemiological findings of the British Ophthalmological Surveillance Unit // Br J Ophthalmol. 2018. Vol. 102, No. 9. P. 1298–1302. DOI: 10.1136/bjophthalmol-2017-310671

[29] Héron E, Bourcier T. Scleritis and episcleritis. J Fr Ophtalmol. 2017;40(8):681–695. DOI: 10.1016/j.jfo.2017.04.007

[30] Héron E., Bourcier T. Sclérites et épisclérites // J Fr Ophtalmol. 2017. Vol. 40, No. 8. P. 681–695. DOI: 10.1016/j.jfo.2017.04.007

[31] Bielefeld P, Saadoun D, Héron E, et al. Scleritis and systemic diseases: What should know the internist? Rev Med Interne. 2018;39(9):711–720. DOI: 10.1016/j.revmed.2018.02.001 (In Fran.)

[32] Bielefeld P., Saadoun D., Héron E., et al. Sclérites et maladies systémiques: que doit savoir l’interniste? // Rev Med Interne. 2018. Vol. 39, No. 9. P. 711–720. DOI: 10.1016/j.revmed.2018.02.001

[33] Yoshida A, Watanabe M, Okubo A, Kawashima H. Clinical characteristics of scleritis patients with emphasized comparison of associated systemic diseases (anti-neutrophil cytoplasmic antibody-associated vasculitis and rheumatoid arthritis). Jpn J Ophthalmol. 2019;63(5):417–424. DOI: 10.1007/s10384-019-00674-7

[34] Yoshida A., Watanabe M., Okubo A., Kawashima H. Clinical characteristics of scleritis patients with emphasized comparison of associated systemic diseases (anti-neutrophil cytoplasmic antibody-associated vasculitis and rheumatoid arthritis) // Jpn J Ophthalmol. 2019. Vol. 63, No. 5. P. 417–424. DOI: 10.1007/s10384-019-00674-7

[35] Nevares A, Raut R, Libman B, Hajj-Ali R. Noninfectious Autoimmune Scleritis: Recognition, Systemic Associations, and Therapy. Curr Rheumatol Rep. 2020;22(4):11. DOI: 10.1007/s11926-020-0885-y

[36] Nevares A., Raut R., Libman B., Hajj-Ali R. Noninfectious Autoimmune Scleritis: Recognition, Systemic Associations, and Therapy // Curr Rheumatol Rep. 2020. Vol. 22, No. 4. P. 11. DOI: 10.1007/s11926-020-0885-y

[37] Clavel G, Gabison E, Semerano L. Corneal and scleral involvement in inflammatory rheumatic disease: Rheumatologists and ophthalmologists exchanging views. Joint Bone Spine. 2019;86(6):699–705. DOI: 10.1016/j.jbspin.2019.01.014

[38] Clavel G., Gabison E., Semerano L. Corneal and scleral involvement in inflammatory rheumatic disease: Rheumatologists and ophthalmologists exchanging views // Joint Bone Spine. 2019. Vol. 86, No. 6. P. 699–705. DOI: 10.1016/j.jbspin.2019.01.014

[39] Szepessy Z, Barsi Á, Kránitz K, Nagy ZZ. The Evolution of Central Retinal and Choroidal Thickness in Acute Anterior Uveitic Patients with Spondyloarthropathy. J Ophthalmol. 2018;2018:9136017. DOI: 10.1155/2018/9136017

[40] Szepessy Z., Barsi Á., Kránitz K., Nagy Z.Z. The Evolution of Central Retinal and Choroidal Thickness in Acute Anterior Uveitic Patients with Spondyloarthropathy // J Ophthalmol. 2018. Vol. 2018. P. 9136017. DOI: 10.1155/2018/9136017

[41] Ferreira CS, Beato J, Falcão MS, et al. Choroidal thickness in multisystemic autoimmune diseases without ophthalmologic manifestations. Retina. 2017;37(3):529–535. DOI: 10.1097/IAE.0000000000001193

[42] Ferreira C.S., Beato J., Falcão M.S., et al. Choroidal thickness in multisystemic autoimmune diseases without ophthalmologic manifestations // Retina. 2017. Vol. 37, No. 3. P. 529–535. DOI: 10.1097/IAE.0000000000001193

[43] Tetikoglu M, Temizturk F, Sagdik HM, et al. Evaluation of the Choroid, Fovea, and Retinal Nerve Fiber Layer in Patients with Rheumatoid Arthritis. Ocul Immunol Inflamm. 2017;25(2):210–214. DOI: 10.3109/09273948.2015.1095303

[44] Tetikoglu M., Temizturk F., Sagdik H.M., et al. Evaluation of the Choroid, Fovea, and Retinal Nerve Fiber Layer in Patients with Rheumatoid Arthritis // Ocul Immunol Inflamm. 2017. Vol. 25, No. 2. P. 210–214. DOI: 10.3109/09273948.2015.1095303

[45] Kurt A, Kurt EE, Kilic R, et al. Is choroidal thickness related with disease activity and joint damage in patient with rheumatoid arthritis. Bratisl Lek Listy. 2017;118(1):23–27. DOI: 10.4149/BLL_2017_005

[46] Kurt A., Kurt E.E., Kilic R., et al. Is choroidal thickness related with disease activity and joint damage in patient with rheumatoid arthritis // Bratisl Lek Listy. 2017. Vol. 118, No. 1. P. 23–27. DOI: 10.4149/BLL_2017_005

[47] Ten Berge JC, Schreurs MWJ, van Daele PLA, Rothova A. Autoimmunity in uveitis. Acta Ophthalmol. 2018;96(5):481–485. DOI: 10.1111/aos.13652

[48] Ten Berge J.C., Schreurs M.W.J., van Daele P.L.A., Rothova A. Autoimmunity in uveitis // Acta Ophthalmol. 2018. Vol. 96, No. 5. P. 481–485. DOI: 10.1111/aos.13652

[49] D’Ambrosio EM, La Cava M, Tortorella P, et al. Clinical Features and Complications of the HLA-B27-associated Acute Anterior Uveitis: A Metanalysis. Semin Ophthalmol. 2017;32(6):689–701. DOI: 10.3109/08820538.2016.1170158

[50] D’Ambrosio E.M., La Cava M., Tortorella P., et al. Clinical Features and Complications of the HLA-B27-associated Acute Anterior Uveitis: A Metanalysis // Semin Ophthalmol. 2017. Vol. 32, No. 6. P. 689–701. DOI: 10.3109/08820538.2016.1170158

[51] Barut K, Adrovic A, Şahin S, Kasapçopur Ö. Juvenile Idiopathic Arthritis. Balkan Med J. 2017;34(2):90–101. DOI: 10.4274/balkanmedj.2017.0111

[52] Barut K., Adrovic A., Şahin S., Kasapçopur Ö. Juvenile Idiopathic Arthritis // Balkan Med J. 2017. Vol. 34, No. 2. P. 90–101. DOI: 10.4274/balkanmedj.2017.0111

[53] Hayworth JL, Turk MA, Nevskaya T, Pope JE. The frequency of uveitis in patients with juvenile inflammatory rheumatic diseases. Joint Bone Spine. 2019;86(6):685–690. DOI: 10.1016/j.jbspin.2019.06.001

[54] Hayworth J.L., Turk M.A., Nevskaya T., Pope J.E. The frequency of uveitis in patients with juvenile inflammatory rheumatic diseases // Joint Bone Spine. 2019. Vol. 86, No. 6. P. 685–690. DOI: 10.1016/j.jbspin.2019.06.001

[55] Celis R, Cuervo A, Ramírez J, Cañete JD. Psoriatic Synovitis: Singularity and Potential Clinical Implications. Front Med (Lausanne). 2019;6:14. DOI: 10.3389/fmed.2019.00014

[56] Celis R., Cuervo A., Ramírez J., Cañete J.D. Psoriatic Synovitis: Singularity and Potential Clinical Implications // Front Med (Lausanne). 2019. Vol. 6. P. 14. DOI: 10.3389/fmed.2019.00014

[57] Cantini F, Niccoli L, Nannini C, et al. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Semin Arthritis Rheum. 2017;47(2):183–192. DOI: 10.1016/j.semarthrit.2017.03.008

[58] Cantini F., Niccoli L., Nannini C., et al. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis // Semin Arthritis Rheum. 2017. Vol. 47, No. 2. P. 183–192. DOI: 10.1016/j.semarthrit.2017.03.008

[59] Duica I, Voinea LM, Mitulescu C, et al. The use of biologic therapies in uveitis. Rom J Ophthalmol. 2018;62(2):105–113.

[60] Duica I., Voinea L.M., Mitulescu C., et al. The use of biologic therapies in uveitis // Rom J Ophthalmol. 2018. Vol. 62, No. 2. P. 105–113.

[61] Turk MA, Hayworth JL, Nevskaya T, Pope JE. Ocular manifestations in rheumatoid arthritis, connective tissue disease and vasculitis: a systematic review and meta-analysis. [published online ahead of print, 2020 May 1] J Rheumatol. 2021:48(1):25–34. DOI: 10.3899/jrheum.190768

[62] Turk M.A., Hayworth J.L., Nevskaya T., Pope J.E. Ocular manifestations in rheumatoid arthritis, connective tissue disease and vasculitis: a systematic review and meta-analysis [published online ahead of print, 2020 May 1] // J Rheumatol. 2021. Vol. 48, No. 1. P. 25–34. DOI: 10.3899/jrheum.190768

[63] Accorinti M, Okada AA, Smith JR, Gilardi M. Epidemiology of Macular Edema in Uveitis. Ocul Immunol Inflamm. 2019;27(2): 169–180. DOI: 10.1080/09273948.2019.1576910

[64] Accorinti M., Okada A.A., Smith J.R., Gilardi M. Epidemiology of Macular Edema in Uveitis // Ocul Immunol Inflamm. 2019. Vol. 27, No. 2. P. 169–180. DOI: 10.1080/09273948.2019.1576910

[65] Aydin E, Atik S, Koc F, et al. Choroidal and central foveal thickness in patients with scleroderma and its systemic associations. Clin Exp Optom. 2017;100(6):656–662. DOI: 10.1111/cxo.12498

[66] Aydin E., Atik S., Koc F., et al. Choroidal and central foveal thickness in patients with scleroderma and its systemic associations // Clin Exp Optom. 2017. Vol. 100, No. 6. P. 656–662. DOI: 10.1111/cxo.12498

[67] Gascon P, Jarrot PA, Matonti F, Kaplanski G. Retinal vasculitis and systemic diseases. Rev Med Interne. 2018;39(9):721–727. DOI: 10.1016/j.revmed.2018.04.013

[68] Gascon P., Jarrot P.A., Matonti F., Kaplanski G. Vascularites rétiniennes et maladies systémiques // Rev Med Interne. 2018. Vol. 39, No. 9. P. 721–727. DOI: 10.1016/j.revmed.2018.04.013

[69] Häuser W, Fitzcharles MA. Facts and myths pertaining to fibromyalgia. Dialogues Clin Neurosci. 2018;20(1):53–62. DOI: 10.31887/DCNS.2018.20.1/whauser

[70] Häuser W, Fitzcharles MA. Facts and myths pertaining to fibromyalgia // Dialogues Clin Neurosci. 2018. Vol. 20, No. 1. P. 53–62. DOI: 10.31887/DCNS.2018.20.1/whauser

[71] Adiguzel S, Palamar M, Yargucu F, et al. Evaluation of Ocular Surface and Meibomian Glands in Patients With Scleroderma. Cornea. DOI: 10.1097/ICO.0000000000002551

[72] Adiguzel S., Palamar M., Yargucu F., et al. Evaluation of Ocular Surface and Meibomian Glands in Patients with Scleroderma // Cornea. DOI: 10.1097/ICO.0000000000002551

[73] Szucs G, Szekanecz Z, Aszalos Z, et al. A Wide Spectrum of Ocular Manifestations Signify Patients with Systemic Sclerosis. Ocul Immunol Inflamm. 2021;29(1):81–89. DOI: 10.1080/09273948.2019.1657467

[74] Szucs G., Szekanecz Z., Aszalos Z., et al. A Wide Spectrum of Ocular Manifestations Signify Patients with Systemic Sclerosis // Ocul Immunol Inflamm. 2021. Vol. 29, No. 1. P. 81–89. DOI: 10.1080/09273948.2019.1657467

RIGHTS & PERMISSIONS

Karpova D.A., Savina E.E., Ponomareva M.N., Lushpaeva Y.A., Partikeeva I.M.